PPADS tetrasodium salt
Modify Date: 2024-01-11 15:13:26
PPADS tetrasodium salt structure
|
Common Name | PPADS tetrasodium salt | ||
|---|---|---|---|---|
| CAS Number | 192575-19-2 | Molecular Weight | 599.305 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C14H10N3Na4O12PS2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PPADS tetrasodium saltPPADS tetrasodiuma is a non-selective P2X receptor antagonist. PPADS tetrasodiuma blocks recombinant P2X1, -2, -3, -5 with IC50s ranging from 1 to 2.6 μM. PPADS tetrasodiuma blocks native P2Y2-like (IC50~0.9 mM) and recombinant P2Y4 (IC50~15 mM) receptors. PPADS tetrasodiuma is an inhibitor of the reverse mode of the Na/Ca²⁺exchanger in guinea pig airway smooth muscle[1][2]. |
| Name | Pyridoxal phosphate-6-azo(benzene-2,4-disulfonic acid) tetrasodium salt hydrate |
|---|---|
| Synonym | More Synonyms |
| Description | PPADS tetrasodiuma is a non-selective P2X receptor antagonist. PPADS tetrasodiuma blocks recombinant P2X1, -2, -3, -5 with IC50s ranging from 1 to 2.6 μM. PPADS tetrasodiuma blocks native P2Y2-like (IC50~0.9 mM) and recombinant P2Y4 (IC50~15 mM) receptors. PPADS tetrasodiuma is an inhibitor of the reverse mode of the Na/Ca²⁺exchanger in guinea pig airway smooth muscle[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | PPADS tetrasodiuma (1-30 μM; 10-50 minutes) inhibits Na+/Ca2+ exchanger reverse mode (NCXREV) in a time- and concentration dependent manner[2]. PPADS tetrasodiuma is effective at other native and recombinant P2XRs. At human P2XRs sensitivity to PPADS tetrasodiuma depended on the subtype and was highest at the hP2X1, -2, -3, -5, and -7Rs with an IC50 of ∼1–3 and ∼30 μM for the hP2X4R[3]. |
| In Vivo | PPADS tetrasodiuma (15-60 mg/100g body weight (BW); i.p.; every 12 hours for 8 days) inhibits glomerular mesangial cells (MC) proliferation without altering proliferation of non-MC in vivo in mesangial proliferative glomerulonephritis[4]. Animal Model: Male Sprague-Dawley ratsweighing 160 to 200 g (anti-Thy1 disease mode)[4] Dosage: 15 mg/100g BW, 30 mg/100g BW, 60 mg/100g BW Administration: i.p.; every 12 hours for 8 days (the first PPADS injection was administered 60 minutes after disease induction, and the loading dose always contained double the amount of PPADS compared to the following injections.) Result: Specifically and dose-dependently reduced early (day 3) glomerular mesangial cell proliferation without altering proliferation of non-MC. |
| References |
[3]. Einfluss von ATP und seinen Derivaten auf die Aktivierung von Monozyten. |
| Molecular Formula | C14H10N3Na4O12PS2 |
|---|---|
| Molecular Weight | 599.305 |
| Exact Mass | 598.903442 |
| PSA | 288.30000 |
| LogP | 3.77900 |
| Storage condition | 2-8°C |
| Safety Phrases | S22-S24/25 |
|---|
| Tetrasodium 4-[(E)-{4-formyl-5-hydroxy-6-methyl-3-[(phosphonatooxy)methyl]pyridin-2-yl}diazenyl]benzene-1,3-disulfonate |
| Tetrasodium 4-[(E)-{4-formyl-5-hydroxy-6-methyl-3-[(phosphonatooxy)methyl]-2-pyridinyl}diazenyl]-1,3-benzenedisulfonate |
| PPADS (sodium salt) |
| 1,3-Benzenedisulfonic acid, 4-[(E)-2-[4-formyl-5-hydroxy-6-methyl-3-[(phosphonooxy)methyl]-2-pyridinyl]diazenyl]-, sodium salt (1:4) |
| MFCD11046026 |